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Endotoxemia and Human Liver Transplantation 
I. Yokoyama, S. Todo, T. Miyata, R. Selby. A.G. Tzakis, and T.E. Starzl 
ALTHOUGH orthotl)pic liver transplantation ha,; be-
come the preferred treatment for many kinds of 
end-stage liver disease. the operation still has a signiticant 
pcrioperative morbidity and monalit\.' Problems that can 
jeopardize or preclude success despil<.: a seemingly perfect 
donor and recipient operation include unexpected coagulop,\' 
thy with hemorrhage. cardiovascular collapse, acute renal 
failure, and respiratory insufficiency. Complications of the 
same kind have been attributed to endotoxemia in experimen-
tal animals or in non transplant patients with portal vein 
occlusion,2 intestinal ischemia;' cirrhosis! and severa I other 
surgical conditions. j 
In dogs submitted to liver replacement, a wave of endotox-
emia can alwaY'S be demonstrated during and after the 
transplantation'" Consequently. we have looked systemati-
cally for evidence of en do toxemia in a randomly select.ed 
group of 90 liver transplantations in adult humans. We found 
a striking association between perioperative blood endotoxin 
levels, the difliculty of convalescence, and the ultimate 
outcome. 
MATERIALS AND METHODS 
Case Material 
Eighty-one adult patients who were 44.0 ± 1.3 (SE) years old (range 
18 to 66) had 90 orthotopic liver transplantations between March 15 
and August 15. 1988. Males were the recipients of 52 (64.2%) of the 
grafts. During this .'i-month period, investigations were conducted in 
50% of all transplantations, t he constituency of the studied vs 
nonstudied groups being determined primarily by availability of the 
investigators. 
Parenchymal disease. of which postnecrotic cirrhosis was the most 
common example, was the principal indication for liver transplanta-
tion (Table 1) Other broad diagnostic categories were cholestatic 
disease, such as primary biliary cirrhosis, miscellaneous disease 
including hepatic malignancies, and failure of a previous gran 
necessitating rctransplantation (Table I). The workup of the recipi-
ents included a complete set of standard liver function tests. 
However, the heterogeneity of native diseases as well as the 
variability of liver function within specific diseases precluded the use 
of these results to classify disease severity.' Instead, the need for 
transplantation and, therefore, the degree of illness of each patient 
was defined prospectively by the criteria for urgency used for the 
United Network for Organ Sharing (UNOS) distribution system.' 
I. Working, in school 
2. Confined (0 home, self-cil re 
3. Home, requiring professional care 
4. Hospital bound, not in intensive care unit (ICU) 
5. leu bound. not ventil:ltor dependent 
6. In ICU. un ventilaLUr, oftcn unconscious 
The Transplant Operations 
All donor procurements were with previously described in situ 
techniques."'" The livers were preserved for 14.1 ± 0.7 (SF) hours 
(range:1 to 32) with University of Wisconsln (UW) solution.'" 
Oon,lr lymphoid tissue was obtained for standard HLA typing and 
for the performance of a standard cytotoxic antibody crossmatch 
with recipient serum. The results of these studies did not influence 
ca~c selection. since they wer\' not ~fhIwn until after the transpLlnta' 
tion. 
The transplantations were pc, ',lIlllld \\ ith lechni4ilcs that could 
be varied according to the needs of the individual recipients.' 'The 
principles were removal of the diseased native liver and placement of 
the graft in as anatomically normal a way as possible (Fig I). During 
the (Gta] hepatectomy and sewing in of the new organ, a motor-
driven venovenous bypass without heparin""" was used in all but 3 
transplantations to prevent venous hypertension elf the occluded 
inferior vena caval and splanchnic venous beds. Even with l his 
technique, it is necessary to accept 15-30 minutes of portal occlUSion 
time during the performance of the portal venous anastomosis. 
The anhepatic phase was counted from the time when the 
recipient hepatic circulation was interrupted to the time when portal 
or arterial circulation was restored to the graft. Throughout the 
operation, particularly during the anhepatic phase. serum lactatc, 
blood glucose, and blood gases were measured at frequent .tntervals. 
Coagulation was monitored with thromboelastography and supple-
mentary measuremem of platelet counts, prothrombin times, and 
other parameters. ,,' 
Biliary tract reconstruction was with choledochocholedochostomv 
or choledochojejunostomy to a Roux limb (Fig I). At the conclusion 
of the operation, the total biood product administration wa, re 
corded. 
Immunosuppression and Rejection 
All patients were treated with CyA and prednisonc to which 
azathioprine (AZA) was added variably if the white blood eel! count 
was above SOOO/mm). Rejection was treated with 1 g boluses of 
steroids and an increased maintenance dose of prednisone. OKT:l 
MAb was given when steroid-resi,tant rejection was diagnosed. 
when poor renal function prevented the adminis[ption of adequate 
CyA doses, or when accelerated rejection was suspected to be the 
cause of primary graft nonfunction. In several patients whose grafts 
failed to function, one or more trealments with plasmapheresis were 
given with the hope that antibodies or some other undetected 
harmful substance could be removed therebv. 
Because the causes of primary graft nonfunction or early patient 
death arc not easy to determine. "" 18 grafts that were lost within 7 
days by death or retransplantation were kept in a separate category 
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Table 1. Indications for the Transplantation of 
90 Liver Grafts 
No. of 
Grafts 
Failed 
Number of Within 
Category Diagnosis Grafts First Month 
Parenchymal liver Cirrhosis, idiopathic 33 (9) 
disease Cirrhosis, HBsAg + 2 (0) 
Cirrhosis, auto-
immune 5 (1) 
Cholestatic Primary biliary 
liver disease cirrhosis 12 (2) 
Sclerosing 
cholangitis 4 (0) 
Caroli's disease 1 (0) 
Miscellaneous Fulminant hepatitis 2 (1) 
Malignant tumor 7 (0) 
Budd-Chiari 
syndrome 2 (0) 
Graft failure" 1. Rejection 
18 days-2 years 7 (2) 
2. Hepatitis 
36-142 days 2 (1) 
3. Recurrent tumor 
19 months (0) 
4. Undetermined 
1-11 days 12 (8) 
Total 90 (24) 
81. 221 ± 89.1 (SE) days 
2. 36 and 142 days 
3. 19 months 
4. 4.5 ± 1.0 (SE) days 
in which the role of an immune event was considered unknown. With 
the 72 livers that survived for more than 7 days, rejection was 
categorized as (I) no clinical or histologic evidence of rejection 
(n = 19), (2) clinical or histologic evidence of rejection that re-
quired increased steroids (n = 28), (3) evidence of rejection that 
required increased steroids plus OKT3 treatment within the I month 
period of the study (n = 25). In group 3, a histologic diagnosis was 
made in 16 recipients, but in 9, OKT3 was given blindly, based on 
the clinical findings of rejection that was so severe that coagulation 
defects made biopsy unsafe. 
Special Infectious Disease Studies 
Culture Data. Aerobic and anaerobic bacteriologic, fungal, and 
viral cultures were obtained preoperatively in all of the patients. Six 
patients went to the operating room infected. In 3, OL transplant 
was performed in the presence of a positive blood culture, and in 3 
more, either pneumonia or peritonitis was present with a positive 
sputum or peritoneal fluid culture. Five of these 6 infected patients 
were undergoing retransplantation for a failed graft; the sixth had 
fulminant hepatic failure. All 6 patients were treated with appropri-
ate antibiotic therapy preoperatively and intraoperatively. 
Endotoxin Measurements. Platelet-poor blood samples of peri ph-
eral venous blood were obtained with a sterile technique with 
venipuncture or through an indwelling catheter and were stored at 
-80°C after 10 minutes centrifugation at 3000 rpm. The samples 
were obtained immediately preoperatively (stage. 1 ), at the end of the 
anhepatic phase just before restoring graft circulation (stage 2), 1 
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Fig 1. The standard technique of orthotopic liver transplan' 
tatlon, showing the two methods of biliary tract reconstruc· 
tion. 
day postoperatively (stage 3), 3 days postoperatively(stage 4), and 7 
days postoperatively or the day closest to 7 in the event of graft loss 
(stage 5). For endotoxin assay, 21.220.32 molll perchloric acid, 0.18 N 
NaOH, and Toxicolor* with pH 8.0 Tris-HCI buffer was used for the 
chromogenic endotoxin assay with limulus coagulation enzymes. 
The standard curve was plotted using Escherichia coli 0111:B4 
endotoxin, Westphal type (Difco Laboratories Inc., Detroit MI), in 
distilled water. 
Statistical Analyses 
Survival for any graft was the time from transplantation to patient 
death or to graft replacement, if this was done. Maximum credit for 
any graft survival was 31 days. 
Cumulative graft survival was obtained with univariate analvKDiDK~D 
and the Cox proportional hazards model was used for multivariate 
analysis in order to examine the influence of various perioperative 
factors on graft survival. BMDP Statistical Software package was 
employed (University of California Los Angeles. California).24 To 
examine the relationship between endotoxin and total bilirubin, 
GOT, GPT, albumin,lactate, amount of blood transfusion, duration 
of cold ischemic time, and duration of anhepatic phase, Pearson 
correlation coefficients were calculated. t· Test was used to determine 
whether the mean values of endotoxin differed between platelet 
transfusion. urgency status, preoperative infection, and lymphocyto-
toxic crossmatch. Statistical values were considered significant when 
p value was less than 0.05. Analyses were performed with all 90 
transplantations initially and then also with only the 68 primary 
transplantations. 
*Lot No. 310051, a commercially available reagent consisting of 
lyophilized amebo\:}'te lysate from Tachypleus trident at us and the 
synthetic chromogenic substrate Boc-Leu-Gly-Arg-p-nitroanilide, 
Seikagaku Kogyo, Ltd., Tokyo, Japan. 
ENDOTOXEMIA AND LIVER TRANSPLANTATION 
RESULTS 
Graft Survival 
Of the 90 grafts, 66 (73.3%) survived to the end of the first 
month. Calculated with a ceiling of 31 days, the mean graft 
survival was 26.3 ± 1.3 (SE) days. The I-month patient 
survival was 86.4% (70/81). Of the 24 graft losses, only 11 
were coincident with death of the recipient. 
The 24 grafts that failed were designated group A, and the 
other 66 were called group B. The mean ages of the recipients 
in group A and group B were 45 and 42 years, respectively 
(p> 0.05), and the male representation was 58.3 and 73.7% 
(p > 0.05). 
Conditions Predisposing to Graft Death 
There was a 25% incidence of graft death (10 of 40) after 
primary transplantation in patients with parenchymal he-
patic disease. This was higher than with the other native 
disease categories (Table I). However, the greatest risk of 
graft death by far was in patients undergoing retransplanta-
tion after failure of a first graft, especially if this was soon 
after the primary operation. Of the 24 graft failures, 11 were 
after retransplantation; the failure rate with this indication 
for operation was 50% (11/22) (Table 1). 
One factor contributing to the low success rate with 
retransplantation was the so-called nonabandonment policy 
of transplanting a third graft if a second one failed. Thus, the 
22 retransplantations in Table I were performed in only 18 
patients. Of the 4 patients who had consecutive retransplan-
tat ions and who, therefore, used a total of 8 livers after 
failure of their primary grafts, only 1 lived for as long as 31 
days, and he eventually died after 55 days. 
In 12 of the 22 retransplantations in Table 1, there was no 
obvious explanation for why the previous attempt 4.5 ± 1.0 
(SE) days earlier (range 1 to 11) had failed. In 8 of these 12 
retransplantations, the effort was unsuccessful, a discourag-
ing record comparable to that reported earlier from our 
center under similar circumstances.25 Retransplantation was 
more successful when the reason for graft failure was known, 
even if this was rejection (Table 1). One reason probably was 
the later timing of the retransplantations for rejection, 
hepatitis, and recurrent tumor. These were 220.8 ± 89.1 
(SE) days (range 18 to 730) after the primary grafting 
(Table 1). 
Timing and Findings with Graft Death 
Graft death occurred 1-26 days postoperatively after a mean 
time of 8.5 ± 1.5 (SE) days. Eighteen of the 24 grafts became 
available for pathologic examination, either at retransplanta-
tion or at autopsy. In the other 6 cases in which autopsy was 
denied, a final graft diagnosis was reached from the clinical 
events, premortem hepatic biopsies, and infectious disease 
data. 
The majority of the failed grafts had necrosis or severe 
ischemic injury (Table 2). The clearest examples were in the 
9 grafts that had such complete nonfunction that retransplan-
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Table 2. Timing and Findings With 24 Graft Deaths 
No. of Average 
Diagnosis Grafts Survival (days) 
Graft necrosis 
(primary nonfunction) 9 2.5 
Ischemia plus sepsis 4 9.5 
Sepsis (plus secondary 
liver failure) 4 10.8 
Rejection (plus sepsis) 2 7 
Humoral rejection, A to 0 
(plus sepsis) 6 
Cytomegalovirus hepatitis 25 
Bile duct disruption 10 
Intraperitoneal bleeding 7 
Portal vein thrombosis 
Total 24 
tation or death followed an average of 2.5 days later. 
Ischemic injury with the supervention of sepsis led more 
slowly to the same result after an average of 9.5 days in 4 
other grafts (Table 2). Sepsis was thought to have caused 
delayed hepatic failure in 4 additional patients. Humoral or 
cellular rejection was the primary diagnosis in 3 patients who 
became septic secondarily (Table 2). Technical causes of 
death included disruption of a biliary anastomosis and shock, 
rupture of a splenic artery aneurysm, and portal vein 
thrombosis (Table 2). 
Six patients underwent transplantation while infected. 
Three had positive blood cultures, 2 had culture-proven 
bacterial peritonitis, and 1 had pneumonia. The organisms 
cultured were Enterobacter cloacae, Enterobacter aero-
genes, Acinetobacter anitratus, Pseudomonas aeruginosa, 
Escherichia coli, Klebsiella pneumoniae, and Candida albi-
cans. Multiple organisms were found in 3 patients. Five of 6 
grafts transplanted into the infected environment failed after 
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Fig 2. Plasma endotoxin levels in transplantations that 
failed vs those that succeeded. Data were from 90 transplan-
tations (68 primary and 22 retransplantations). Stage 1, 
preoperative. Stage 2, end of anhepatlc phase. Stage 3, 1 day 
postoperative. Stage 4, 3 days postoperative. Stage 5, 7 days 
postoperative or day of sampling closest to 7 days. Mean ± 
SE. 
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Fig 3. Same study as in Fig 2 but for only 68 primary 
transplantations. Stages as in Fig 2. Mean ± SE. 
2-20 days, and the sixth failed 2.5 months later. All patients 
died. Five of these 6 patients were undergoing emergency 
retransplantation, and the other had fulminant hepatic 
failure. 
Endotoxemia 
Controls. With the method used in this study, endotoxin 
was not detectable in the plasma of 24 normal volunteers 
« I 0 pg/ml). Plasma samples from 6 cadaveric liver donors 
were analyzed. The samples contained 16.7, 1.4, J. 7, 1.4,0.1, 
and 19.5 pg/ml endotoxin. Thus, 2 of the donors had 
abnormally high endotoxin levels. 
Failed (group Ai vs successful (group B) grafts. 
Endotoxin concentrations were abnormally elevated in both 
groups A and B. However, the 24 patients in group A had 
considerably higher preoperative endotoxin levels than the 
patients in group B, and this differential was maintained 
throughout all stages of sampling. The highest values in both 
groups were at the end of the anhepatic phase (Fig 2). When 
the retransplantations were removed from both groups and 
only primary transplantations were considered (Fig 3), the 
relative endotoxemia in group A was still evident. 
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Fig 4. Effect of preoperative endotoxin on outcome in gO 
transplantations (68 primary and 22 retransplantatlon). 
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Fig 5. Same study as in Fig 4 but for only 68 primary 
transplantations. 
Endotoxemia vs rnortalitv. When the preoperative 
plasma endotoxin concentrations were 2: 10 pg/ml, graft 
survival was significantly reduced (Fig 4). Because the 
inclusion of 22 retransplantations could have distorted the 
results, a separate analysis was conducted of the 68 primary 
transplantations (Fig 5). The influence of preexisting endo-
toxemia was equally evident in this culled group. 
The adverse implications on graft survival of elevated 
plasma endotoxin at the end of the anhepatic period (Figs 6, 
7) or on day 1 (Figs 8, 9) also were apparent with the total 90 
transplantations (Figs 6, 8) or with the subgroup of 68 
primary grafts (Figs 7, 9). 
Endotoxemia vs rejection. There were 72 transplanta-
tions in which graft survival for at least a week allowed 
rejection to be assessed. Although there was a trend toward 
greater endotoxemia in patients who ultimately developed 
severe enough rejection to require OKT3, this was significant 
( p < 0.05) compared to patients with mild or no rejection 
only on postoperative day 3 (Fig 10). 
Endotoxemia and primary graft non function. The 9 
grafts with immediate hemorrhagic necrosis (Table 2) were 
classified as having primary nonfunction. Positive cytotoxic 
crossmatches with their donors were demonstrated with the 
sera of only 2 of the 9 recipients (Table 3) .. Patient 4 died 
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Fig 7. Same study as in Fig 6 but for only 68 primary 
transplantations. 
before another liver could be found. Five other patients died 
within a month in spite of retransplantation, usually with 
similar nonfunction of the next liver. Only 3 of the 9 patients 
survived (Cases 1,2, and 8). 
Although none of these 9 patients was thought to be 
infected preoperatively, the plasma endotoxin rose signifi-
cantly between the beginning of the case and the end of the 
anhepatic phase. By this time (Table 3), the plasma endo-
toxin was between 101 and 295 pglml in 7 of the 9 recipients 
(Table 3). 
Other associations with graft death and endotoxemia. 
Eight other factors associated with graft loss by Kaplan-
Meier univariate analysis are listed in Table 4. In Table 5 are 
summarized correlation analysis or t-test, showing that total 
bilirubin, GOT, GPT, creatinine, lactate, amount of blood 
transfusion, urgency status, cold ischemic time, and preoper-
ative infection were associated with endotoxemia before, 
during, or after the transplantation. 
With the Cox proportional hazards model, the most 
powerful independent factors associated with graft death 
were endotoxemia ~ 100 pglml at the end of the anhepatic 
period, lactate level greater than 10 mmolll at the same time 
and SGPT ~OMM lUll preoperatively (Table 6). ' 
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Fig 8. Correlation of endotoxin level 1 day postoperatively 
on graft survival for all 90 transplantations. (Two of 90 grafts 
failed before reaching this stage.) 
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DISCUSSION 
Endotoxin is a macromolecule of which the most specific and 
active component is lipid A.26 However, it has been recog-
nized increasingly that protein and polysaccharide compo-
nents of the molecule can influence its potency and 
specificityY·28 Because endotoxin is found in the wall of 
gram-negative bacteria that are indigenous to the gastrointes-
tinal tract, an enteric problem must be suspected when 
symptomatic endotoxemia is diagnosed. 29 
Almost no information exists about endotoxemia in he-
patic transplantation despite the fact that changes might be 
predicted. Intravenous endotoxin is removed mainly by the 
Kuppfer cells of the liver.30.3) Not only is this detoxification 
system absent during the anhepatic phase of transplantation, 
but there is a subsequent transformation in the graft whereby 
donor Kuppfer cells are replaced with macrophages of 
recipient origin.n .)) Finally, the operation exposes the liver to 
intestinal bacteria that reach the liver in splanchnic blood 
T 
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STAGE 1 STAGE 2 STAGE 3 STAGE 4 STAGE 5 
Rejection Treated with Steroid 
.... t. 
(n:28) 
Rejection Treated with OKT3 
I (n=2S) 
No Rejection 
-L (n:19) 
Fig 10. Endotoxin levels In 72 patients In whom rejection 
could be assessed. Group A, no rejection. Group B, mild or 
moderate rejection. Group C, severe rejection requiring OKT3 
therapy. Stages are the same as in Fig 2. Mean ± SE. 
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Table 3. Primary Nonfunction of 9 Grafts 
Endotoxin Concentration (pg / ml) 
No of 
Previous PO· 
Case Grafts Preop Anhepatic day 1 
1 0 17.7 111.2 26.0 
2 0 0 15.7 42.5 
3 0 8.9 199.3 74.4 
4 0 13.3 101.1 
5 18.7 153.3 34.7 
6 40.1 295.0 60.0 
7 0 41.8 137.2 67.6 
8 0 47.6 13.4 60.6 
9 0 10.8 135.2 
"PO. postoperative. 
and through the biliary tract and then leak through to the 
system circulation.34.3 ' Thus, it was not surprising in healthy 
dogs to always find rises in the plasma endotoxin during and 
after liver replacement. 6 
What this wave of endotoxemia means is an unresolved 
matter. Although there is evidence that small quantities of 
Graft 
PO PO Preop Survival 
day 3 day 7 Status Crossmatch (Days) 
4 3 
7.8 3 3 
73.3 4 3 
4 + 2 
5 3 
6 + 2 
5 2 
12.1 12.5 4 7 
5 
endotoxin can cause serious or lethal syndromes in animals 
and humans/· i6 a cause and effect relationship may be 
difficult to establish in specific situations.37 One reason is that 
the presence of endotoxin, even in large amounts, may not 
necessarily be associated with symptoms.38 Another reason is 
that the responses elicited by endotoxin are not specific or 
Table 4. Various Factors Affecting Graft Survival 
Mean Survival 
Graft No. Time (Days) 
Factor Category (Graft Death) (Mean ± SE) Statistics 
Total bilirubin (mg I dl) <5 38 (7) 28.1 ± 1.9 NS· 
".5. <10 15 (3) 26.9 ± 3.2 
:>:10 37 (14) 23.2 ± 2.1 
GOT <80 36 (4) 30.1 ± 1.6 p < 0.001 
(IU II) :>:80. <250 31 (7) 26.8 ± 2.0 
:>:250 23 (13) 18.1 ± 2.9 
GPT <70 38 (4) 29.5 ± 1.7 p < 0.001 
(IU II) ".70.<200 31 (7) 26.9 ± 2.0 
".200 21 (13) 17.9 ± 3.1 
Albumin (g I dl) <3.0 48 (10) 27.2 ± 1.5 NS 
:>:3.0 42 (14) 24.3 ± 2.1 
Lactate (preoperative) <3 71 (13) 28.3 ± 1.3 P < 0.001 
(mmol/l) ".3,<6 9 (4) 23.4 ± 4.7 
".6 10 (7) 13.4 ± 4.2 
Lactate (intraoperative) <5 38 (4) 30.3 ± 1.5 p < 0.0001 
(mmol/l) ".5.<10 30 (7) 26.9 ± 2.0 
".10 22 (13) 16.9 ± 3.0 
Blood transfusions <10 44 (8) 28.2 ± 1.4 p < 0.05 
(units) ".10 46 (16) 23.7 ± 2.0 
Platelet Iransfusion none 57 (18) 25.3 ± 1.7 NS 
yes 33 (6) 27.2 ± 2.0 
Urgency status 2·5 68 (15) 28.5 ± 1.4 p < 0.05 
(preoperative) 6 22 (9) 20.9 ± 2.9 
Cold ischemic time <12 51 (9) 28.1 ± 1.3 p. 0.05 
(hours) ".12 39 (15) 22.8 ± 2.2 
Anhepatic duration <2 62 (18) 27.2 ± 2.0 NS 
(hours) ".2 28 (6) 25.5 ± 1.6 
Lymphocytotoxic Positive 16 (5) 24.1 ± 3.4 NS 
crossmatch Negative 74 (19) 26.6 '" 1.4 
Infection No 84 (19) 27.2 ± 1.3 p<0.01 
Yes 6 (5) 13.5 ± 4.8 
'NS. not significant. 
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Table 5. Correlation Between Various Clinical Parameters 
and Endotoxin Level at Different Stages 
Endotoxin 
Stage 3 
Stage 1 Stage 2 (postop 
Clinical P aramelers (preop) (anhepalic) Day 1) 
Total bilirubin +a + 
GOT + 
GPT + 
Albumin 
Creatinine + + 
Preoperative lactate + 
Intraoperative lactate + + 
Amount of blood transfusion + 
Amount of platelet transfusion 
Urgency status + 
Duration of cold ischemic time 
Duration of anhepatic phase + 
Preoperative infection + 
Lymphocytotoxic crossmatch 
a +. statistically significant p < 0.05; -, not significant. 
unique. 28•39 Endotoxin can induce the release of a complete 
spectrum of biologically active substances, including soluble 
mediators of the inflammatory response and cytokines (Table 
7). Activation of the individual mediators, including the 
cytokines, is induced by a direct effect of the endotoxin on 
complement, macrophages, monocytes, and other formed 
blood elements, including lymphocytes and endothelial cells 
(Table 7). 
The soluble mediators that can be released into the 
circulation or locally as a consequence theoretically could 
have devastating physiologic effects (Table 7), including 
fever, shock, vasodilatation, vasoconstriction, coagulation 
disorders, smooth muscle contraction, endothelial injury, 
chemotaxis, tissue necrosis, and even neuropsychiatric 
changes. In addition, the majority of the mediators have 
immunoregulatory functions, predominantly augmentating 
either cellular or humoral immunoreactivity or both (Table 
7). This latter feature of the soluble mediators may be 
particularly important in the context of transplantation. 
However, what results from exposure to endotoxin could be a 
combination of the effects of many or even all of the 
mediators. The difficulty of interpretation is compounded by 
the fact that many factors other than endotoxin can activate 
the mediators and by the variable functional interactions 
between the mediators themselves.28•4o 
In our patients, high levels of endotoxin at any time, but 
particularly before operation and at the end of the anhepatic 
Table 6. Cox Proportional Hazards Model Analysis Showing 
Factors That Correlate Most Strongly with Postoperative 
Graft Death 
Factor 
Endotoxin 2: 100 pg I ml at stage 2 
GPT 2:200 lUll at stage 1 
Lactate 2: 1 0 mmol I I at stage 2 
pValue 
0.0001 
0.0056 
0.0002 
Relative Risk 
2.3 
2.9 
2.5 
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phase, had more serious prognostic implications than any 
other factor except lactate accumulation. However, it was 
difficult to distinguish cause from effect. Were the high levels 
of endotoxin merely a reflection of the terminally ill state of 
the patient or the transplantation of a suboptimally perform-
ing graft? Or was the preexisting or secondarily appearing 
endotoxin responsible for the failure of multiple organ 
systems, including the new liver? 
The observations most clearly suggesting a cause and 
effect relationship were in the 9 patients who had primary 
nonfunction of their grafts. In these patients, most of the 
endotoxin levels were moderately elevated preoperatively. 
However, large further increases occurred in the plasma by 
the time the new livers were revascularized in 7 of the 9 
patients. The livers acted as if they had been revascularized 
in a hostile environment. Only 2 of the 9 patients had positive 
cytotoxic crossmatches with their donors, but all 9 of the 
livers behaved as if hyperacute rejection had occurred. 
The possibility was discussed two decades ago that endo-
toxin might be able to destroy kidney grafts in a way 
analogous to the hyperacute rejection caused by cytotoxic 
antigraft antibodies.41 At that time, little was known about 
soluble mediators and cytokines. Now, it is easy to conceive 
that these substances, of which many are immunoregulatory 
(Table 7), could participate in an endotoxin-initiated injury, 
a humoral immune reaction, or a combination of these. The 
patient with high endotoxin potential during the anhepatic 
phase could be the liver eater familiar to liver transplant 
surgeons, who destroys successive grafts even though cross-
matches with the donors are negative.42 
If endotoxemia can be shown to be a negative factor in the 
transplantation of the liver or other organs, therapeutic 
strategies might be devised to prevent this complication. 
Possibilities could include the use of anti-endotoxin MAbs43 
or, less specifically, the control of the gram-negative intesti-
nal flora with antibiotics, as described by Weisner et al. 44 
Polymyxin B is an antibiotic with a strong anti-endotoxin 
activity.45 
This study was concerned primarily with recipient endo-
toxin. However, endotoxin also could adversely affect the 
liver and other organs of brain dead donors, particularly if 
these are victims of severe trauma. 5 It was of interest that 2 of 
6 cadaveric donors of livers not used in this study had plasma 
endotoxin levels in the 10-20 pg/ml range. More investiga-
tions on this matter are under way. 
SUMMARY 
Ninety liver transplantations were performed in 81 patients. 
Plasma endotoxin was measured preoperatively, at the end of 
the anhepatic phase, and on postoperative days 1, 3, and 7. 
The presence of high endotoxin levels preoperatively and at 
the end of the anhepatic period was associated with graft 
failure and a high mortality. Patients with primary nonfunc-
tion of their transplants typically had severe endotoxemia. 
Endotoxemia could be a cause rather than an effect of 
perioperative complications and graft loss. 
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Table 7. Soluble Mediators (Including Cytokines) That Are Activated by Endotoxin 
Description of Mediator 
Anaphylatoxirs C3a and C5a Cleavage products of C3 and 
C5 complement 
How Endotoxin Initiates 
Mediator Production Physiologic Consequences 
,\ctivates serum complement Vasodilatation, smooth muscle 
(classic and alternative path- contraction, mononuclear cell 
ways) and neutrophil chemotaxis, 
immunomodulation of humoral 
response 
Prostaglandins Cyclooxygenase pathway from Activates macrophages and Vasodilatation, activate or col-
laborate with other mediators, 
modulate macrophage effect 
leukotfienes 
Platelet activating factor 
(Pt'lF) 
Tissue factor (TF) 
Interleukin I (ll·1) 
Tumor necrosis factor 
(cachectin) 
Colony-stimulating factor 
Gamma-interferon 
Endorphins 
arachidonic acid monocytes 
Lipoxygenase pathway from Activates macrophages and 
arachidonic acid monocytes 
lipid mediators derived from Binds to platelets, neutrophils, 
platelets, neutrophils, baso- etc with mediator release 
phils, mononuclear phago-
cytes, endothelial cel!s 
Glycoprotein from monocyte 
or macrophage cell suriil.ces 
Family of immunoregulator 
cytokines 
Product of activated macro-
phages 
Heterogeneous glycoproteins 
from macrophages and B 
lymphocytes 
lymphokine from activated T 
lymphocytes 
Endogenous opioids 
Activates factor XII (intrinsic 
coagulation pathway), stimu-
lates mononuclear cells (ex-
trinsic coagulation pathway) 
Stimulates mononuclear phago-
cytes and other cells 
Activates macrophages pro-
duction 
Induces production by macro-
phages and B lymphocytes 
Complex pathway· (see ref 40) 
Unknown, could stimulate mono-
nuclear cells 
on function 
Vasoconstriction, activate or 
collaborate with other media-
tors, modulate macrophage 
effect on function 
Platelet aggregation, neutrophil 
degranulation, smooth muscle 
contraction, increased vascu-
lar permeability, hypotension, 
tissue necrosis, modulate en-
dothelial cell function 
Microvascular thrombosis 
Fever, lymphocyte activation, 
coagulation, increases endot-
helial cell adhesiveness, en-
hancement of T and B cell im-
munity, secondarily activate 
PAF, arachidonic acid prod-
ucts, etc 
Fever, induces IL-1 from mononu-
clear and endothelial cells, 
cytotoxic: t,) tumor cells, ampli-
fies microvascular coagulation 
Stimulates proliferation and dif-
ferentiation from marrow-de-
rived precursor cells, acti-
vates mature macrophages to 
produce other mediators 
Increases antibacterial and anti-
tumor activity of macrophages, 
increases expression of Fc 
receptors, augments other 
immune responses, amplifies 
endotoxin effects 
(?vicious cycle) 
Hypotension, analgeSia, behav, 
ior changes, immune regula-
tion (enhancing and suppress-
ing) 
"Alpha and beta interferon are induced by endotoxin directly from B lymphocytes and macrophages, 
From Morrison, Ryan,'8 
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